| January 14, 2021 | ||
|---|---|---|
*Oragenics shares are trading higher after the company issued a letter to shareholders highlighting updates regarding development of its COVID-19 vaccine, Terra CoV-2.(Benzinga) | ||
Oragenics Issues Letter To Stockholders(Benzinga) | ||
Showing posts with label OGEN News. Show all posts
Showing posts with label OGEN News. Show all posts
Wednesday, February 3, 2021
OGEN (14/01/2021 ) event the prices is up - OGEN news
Oragenics news 02/02/2021
*Oragenics Announces Spike Protein Cov-2 S-2P Created By The NIH And Licensed By The Company Demonstrates Protective Immunity In Immunized Mice Challenged With Mouse-adapted Sars-CoV-2 Virus(Benzinga) | ||
Thursday, January 14, 2021
OGEN News proposed phase 1
Oragenics Up 32%
| Mentioned: | OGEN |
By Michael Dabaie
The company in a letter to stockholders provided an update on the Terra CoV-2 vaccine against SARS-CoV-2, saying it expects to file an Investigational New Drug application in the third quarter of 2021.
Oragenics said it added this vaccine candidate as a result of its May 2020 acquisition of Noachis Terra, and immediately began preclinical work. Noachis Terra is now a wholly owned subsidiary of Oragenics.
The company said it holds a nonexclusive intellectual property license from the National Institutes of Health to the prefusion stabilized spike protein vaccine candidate.
The letter to stockholders from Chief Executive Alan Joslyn said the company believes recent Phase 3 data reported relating to the Moderna vaccine supports the concept of utilizing the stabilized spike protein.
The company said work it undertook "supports our expectation to file the IND mid-year with commencement of patient enrollment in the Phase 1 clinical study immediately thereafter. The proposed Phase 1 study protocol is under development."
"While the world's attention is on COVID-19, we also believe that our vaccine may provide some benefit against other coronaviruses that, unfortunately, may emerge or strengthen in the coming years," the letter to stockholders said.
"We firmly believe that even with two or more vaccines projected to be on the market in the coming months, given the size of the worldwide pandemic there will be plenty of demand for the Terra CoV-2 vaccine, once development is successfully completed," the letter said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 14, 2021 11:18 ET (16:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sunday, November 29, 2020
OGEN NEWS CNN FORECAST
Oragenics Inc (NYSE American:OGEN)
The 1 analysts offering 12-month price forecasts for Oragenics Inc have a median target of 2.50, with a high estimate of 2.50 and a low estimate of 2.50.The median estimate represents a +509.76% increase from the last price of 0.41.
Subscribe to:
Posts (Atom)